Cargando…
Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve
[Image: see text] The phosphoinositide kinase PIKfyve has emerged as a new potential therapeutic target in various cancers. However, limited clinical progress has been achieved with PIKfyve inhibitors. Here, we report the discovery of a first-in-class PIKfyve degrader 12d (PIK5-12d) by employing the...
Autores principales: | Li, Chungen, Qiao, Yuanyuan, Jiang, Xia, Liu, Lianchao, Zheng, Yang, Qiu, Yudi, Cheng, Caleb, Zhou, Fengtao, Zhou, Yang, Huang, Weixue, Ren, Xiaomei, Wang, Yuzhuo, Wang, Zhen, Chinnaiyan, Arul M., Ding, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510382/ https://www.ncbi.nlm.nih.gov/pubmed/37605297 http://dx.doi.org/10.1021/acs.jmedchem.3c00912 |
Ejemplares similares
-
Discovery of
a Highly Potent and Selective Dual PROTAC
Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022) -
Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer
por: Qiao, Yuanyuan, et al.
Publicado: (2021) -
PIKfyve regulates melanosome biogenesis
por: Liggins, Marc C., et al.
Publicado: (2018) -
PIKfyve Regulation of Endosome-Linked Pathways
por: de Lartigue, Jane, et al.
Publicado: (2009) -
PIKfyve promotes neuron self-preservation
por: Powell, Kendall
Publicado: (2009)